thought call line
agreement england highlight strong fundament vertex reiter
thesi predic grow cf revenu head remaind
focu us launch trikafta us approval/ reimburs
tripl ou increment sale recent reimburs agreement england
compani cautiou regard launch trikafta us think
forecast sale het-min patient reason given high-unmet need
compel clinic data also forecast increment sale england orkambi
symkevi look see addit upsid like
reimburs orkambi symkevi ww addit approv trikafta
alreadi submit given vertex continu execut commerci
pipelin perspect reiter outperform rate tp
ou reimburs like drive upward revenu revis nearer-term vertex
could expand treatabl popul via reimburs deal new market label
expans new age group believ recent deal uk spain australia
could pressur franc formal agreement trikafta label could expand
includ patient age futur estim addit us patient could
treat group note vertex enrol phase trial trikafta children
age provid addit increment revenu approv think like
posit non-cf pipelin limit credit model set good
risk/reward pipelin like option vertex antitrypsin defici
program data address pt us eu sickl
cell beta thal data limit detail
expect data present least patient note site current
recruit patient phase trial
model updates/risk ep updat due revis revenu
valuat metric
number share
 close
legal entiti disclosur statu non-u analyst us disclosur credit suiss seek busi
compani cover research report result investor awar firm may conflict interest could
affect object report investor consid report singl factor make invest decis
profit tax
associ
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
vertex engag develop commerci therapeut
rare diseas includ main franchis cystic fibrosi
scenario assum dcf valu share
cut sg respect assum
posit proof-of-concept data next gener cf asset
also assum posit data updat pipelin asset vx-
gene-edit system
grey sky scenario model less credit trikafta due
lower expect commerci perform regulatori delay
 close
pipelin updat look cf franchis vertex file ema
trikafta patient older addit phase studi children age current
enrol switch non-cf pipelin vertex expect clinic data
antitrypsin franchis peopl two mutat asset
trial evalu patient multipl dose given day look chang
level function protein blood primari endpoint second asset
current on-going phase
gene therapi crispr-partn franchis vertex expect first clinic data
on-going phase studi sickl cell diseas beta thalassemia
think like venu yet confirm move pain
franchis new asset target channel initi final vertex
expect complet phase studi evalu treatment
mediat focal segment glomerulosclerosi fsg
model adjust made adjust core commerci portfolio reflect
current revenu trajectori guidanc rais updat fy revenu
estim non-gaap ep
weve reduc expens reflect manag commentari figur
vertex residu cf opportun ex revenu loss incom cs dilut cs charl martineau univers toronto octob
compani mention price
evan seigerman certifi view express report accur reflect person view subject compani
secur part compens directli indirectli relat specif recommend view express
report
